Founded in 2021 by Alexandros Pantalis and Adèle James, Phagos engineers bacteriophage (phage) treatments through a proprietary platform that combines microbiology with artificial intelligence. Its patented AI analyses complete phage and bacterial genomes to predict interactions and design precise, adaptable therapies as pathogens evolve. The company’s first commercial focus is veterinary medicine, where it has already secured regulatory authorisation to market personalised phage-based treatments aimed at reducing antibiotic use in livestock. Longer term, Phagos intends to expand these solutions to human health applications. With antimicrobial resistance driving millions of deaths and heavy economic costs, management positions the technology as a scalable global standard for bacterial infection control. The recent €25 million Series A financing provides capital to scale veterinary product deployment, advance the next generation of its AI, and grow the team to support market launches and international expansion. No operating metrics such as revenue or user counts were disclosed in the article.

Total raised

$29M

Funding rounds

1

Latest round

Series A

Latest activity

Oct 2025